A
Amyris Biotech
Creates renewable products, focusing on fuels and chemicals
About Amyris Biotech
Founded in 2003 by a group of scientists from the University of California, Berkeley, including Jay Keasling, Jack D. Newman, Keith Kinkead Reiling, and Neil Renninger, Amyris, Inc. began with a focus on applying synthetic biology to address global challenges. An early significant achievement, supported by a grant from the Bill & Melinda Gates Foundation, was engineering yeast to produce artemisinic acid, a precursor to an effective anti-malarial drug, making the treatment more accessible. Keasling, a professor of chemical and bioengineering, is considered a leading authority in synthetic biology, and his work has been foundational to the company's trajectory.
Read full description
The company's core business revolves around its proprietary Lab-to-Market™ technology platform, which uses genetically engineered microorganisms, primarily yeast, to convert plant-based sugars from sugarcane into a wide array of molecules through fermentation. This process serves as a sustainable alternative to traditional manufacturing methods that often rely on petrochemicals or scarce natural resources. Amyris operates as both a business-to-business (B2B) ingredient supplier and a direct-to-consumer (D2C) brand portfolio manager. For its B2B segment, the company develops and manufactures specialty ingredients for the flavors and fragrances, cosmetics, pharmaceuticals, and nutraceuticals markets, selling them to large corporations. Its D2C model involved creating and marketing its own consumer brands, such as Biossance (skincare) and JVN (haircare), which utilized its bio-manufactured ingredients.
Amyris's product portfolio is diverse, stemming from its flexible production platform. A cornerstone ingredient is squalane, a high-performance emollient traditionally sourced from shark livers, which Amyris produces from sugarcane, thereby offering a sustainable alternative for the cosmetics industry. Another key product is hemisqualane, a plant-based silicone alternative. The company has successfully commercialized over a dozen molecules, including a zero-calorie sweetener (Reb M) and ingredients for fragrances. In early 2023, the Swiss fragrance and cosmetic ingredient maker Givaudan acquired a significant portion of Amyris's cosmetic ingredients portfolio, including squalane and hemisqualane, in a deal that included a long-term manufacturing agreement.
Despite its scientific and commercial successes, the company faced significant financial challenges. After years of operating at a loss, Amyris filed for Chapter 11 bankruptcy protection in August 2023. The restructuring plan involved divesting its portfolio of consumer brands to focus on its core competencies: research and development, and the commercialization of sustainable ingredients for its B2B clients. As part of this transition, long-time CEO John Melo stepped down in June 2023, and Han Kieftenbeld was appointed as interim CEO. The company successfully emerged from bankruptcy in May 2024, with Kathy Fortmann installed as the new CEO to lead a strategy focused on B2B customers.
At a glance
- Status
- Operational
- Founded
- 2003
- Headquarters
- Emeryville, United States
- Listing
- IPO 2010
- Employees
- 991
- Open positions
- 26
- Dealroom signal
- 69.0/100
- Industry
- Chemicals
- Sector
- Chemicals, Biotechnology, Chemistry, Nutrition, Synthetic Biology, Spinout, Biotech and Pharma, Fermentation, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b, b2c
- Investment activity
- 3 companies, latest Sep 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Amyris Biotech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Nov 2021 | $400M | — | Undisclosed | ↗ |
| POST IPO EQUITYOther financing | Apr 2021 | $300M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $270M | 0% |
| 2025 | $270M | 0% |
| 2024 | $270M | 0% |
| 2023 | $270M | 0% |
| 2022 | $270M | -21% |
| 2021 | $342M | +97.4% |
| 2020 | $173M | — |
Growth signals
Latest recorded traffic for Amyris Biotech is 5.7K monthly website visits, down 3.4% over the last three months. Amyris Biotech's team grew 0.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Beauty LabsCambridge, United KingdomDeveloping pioneering technology that will transform Beauty using artificial intelligence and deep learning
$20Mvaluation
MG EmpowerLondon, United Kingdom
→
FetalixPorto, PortugalA regenerative, fetal-inspired solution for treating low back pain through a minimally invasive approach
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institutes of Health
Series A4 investors entered at this stage
Series B and later5 investors entered at this stage
P&G Ventures
Temasek
DSM
Wei-Wu He
John Doerr
Other known investors1 additional known investor
University of California, Berkeley
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Amyris Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Amyris Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.











